Optipharm KRX:153710KOSDAQ
옵티팜 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Optipharm reported revenue of ₩6.5bn, up 13.9% year on year, and operating profit of ₩182m. Optipharm (옵티팜) appeared in 4 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Nov 16 with 4 articles. The most common catalyst was earnings (3).
Filing signals Turnaround Insider buying Screener
Optipharm at a glance from DART filings
- Results trend
- Operating profit in 1 of the last 4 quarters; Q3 2026 operating profit of ₩182m swung to a profit from a loss in the previous quarter.
- Ownership changes
- 2 5%-holder and insider ownership reports in the past 120 days (2 increases, 0 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Optipharm today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Optipharm stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Optipharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩6.5bn | +13.9% | ₩182m margin 2.8% | ₩164m |
| Q2 2026 | ₩6.6bn | +13.8% | −₩206m margin −3.1% | −₩217m |
| Q1 2026 | ₩5.4bn | +9.0% | −₩723m margin −13.5% | −₩754m |
| Q4 2025 derived | ₩6.0bn | +6.5% | −₩321m margin −5.4% | −₩343m |
| Q3 2025 | ₩5.7bn | +18.6% | −₩525m margin −9.2% | −₩547m |
| Q2 2025 | ₩5.8bn | +16.9% | −₩434m margin −7.5% | −₩470m |
| Q1 2025 | ₩4.9bn | +14.4% | −₩1.1bn margin −23.1% | −₩1.1bn |
| Q4 2024 derived | ₩5.6bn | +10.9% | −₩251m margin −4.5% | −₩229m |
Optipharm ranks #1332 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Optipharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Optipharm news Korean headlines
-
Xenotransplantation commercialization momentum: Optifarm acquires cGMP facility
1 more on this story · 1 outlets
-
Optifarm acquires Seedomogen cGMP facility to secure clinical and manufacturing base for xenotransplantation
1 more on this story · 1 outlets